All In Biotech

NDA 009866 · Pharmacia and Upjohn

Solu-Cortef

Hydrocortisone Sodium Succinate · Injection

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1955

Apr 27, 1955

Approved uses

1

Original approval plus efficacy supplements

Registered trials

753

149 Phase 3, 82 recruiting

FAERS reports

9,514

8,627 serious, 2,440 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases:...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 27, 1955 Original approval · Type 2 - New Active Ingredient
4 products under this application
  • SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription
  • SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 100MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
  • SOLU-CORTEF · HYDROCORTISONE SODIUM SUCCINATE EQ 250MG BASE/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 753 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,694
  • infusion related reaction1,275
  • pyrexia1,136
  • fatigue1,130
  • dyspnoea1,011
  • nausea1,001
  • rash974
  • pain955
  • headache945
  • diarrhoea930
  • vomiting922
  • condition aggravated918

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004109
2005138
2006106
2007180
2008183
2009215
2010269
2011380
2012356
2013248
2014307
2015377
2016389
2017311
2018396
2019509
2020518
2021497
2022718
2023815
2024970
2025996
2026527

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Solu-Cortef (Hydrocortisone Sod Succinate)

2024 spending

$123K

Beneficiaries

1,221

1,790 claims

Per beneficiary

$101

$12.02 per unit

View as table
YearSpending
2020$133,432
2021$112,492
2022$134,808
2023$118,982
2024$123,492

Part D: Solu-Cortef (Hydrocortisone Sodium Succ/PF)

2024 spending

$990K

Beneficiaries

7,708

13,384 claims

Per beneficiary

$128

$13.83 per unit

View as table
YearSpending
2020$540,590
2021$623,211
2022$715,904
2023$674,413
2024$989,905

Part B: Solu-Cortef* (HydrocortIsone Sod Succinate*) · HCPCS J1720

2024 spending

$480K

Beneficiaries

7,252

24,926 claims

Per beneficiary

$66

2024 ASP limit $18.89 per unit

View as table
YearSpending
2020$590,909
2021$642,328
2022$680,268
2023$441,127
2024$480,303

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,629 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.